Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TV campaign

- PMLiVE

FDA clears J&J’s breakthrough lymphoma therapy

Imbruvica approved to treat mantle cell lymphoma

- PMLiVE

J&J pays $2bn to settle Risperdal mis-selling claims

Concludes nine-year investigation into marketing activities

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

J&J seeks European digital health entrepreneurs

Digital health mentor programme will culminate in €50,000 challenge

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

New data backs J&J’s ibrutinib efficacy in B cell cancers

Phase II results showcased at European Hematology Association meeting

- PMLiVE

J&J wins silver for nursing campaign at 2013 North America Effie Awards

‘Healing a profession from the inside out’ designed to acknowledge nursing skills

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

- PMLiVE

Johnson & Johnson launches first corporate campaign for decade

Campaign intended to reinforce company values to consumer

- PMLiVE

OTC recovery helps J&J in first-quarter

Recalled products return to market to drive sales

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links